2015—2017年天津医科大学代谢病医院降糖类药物的使用情况分析

Analysis on usage of hypoglycemic agents in Tianjin Medical University Metabolic Diseases Hospital From 2015 to 2017

目的分析天津医科大学代谢病医院降糖类药物的用药情况及用药趋势,为临床合理用药提供依据。方法采用回顾性分析方法,调取2015-2017年天津医科大学代谢病医院降糖类药物相关数据,对降糖类药物品种、销售金额、用药频度(DDDs)、日均药费(DDC)和排序比(B/A)进行统计分析。结果降糖类药物的销售金额和DDDs均呈先下降后上升的趋势。胰岛素的销售金额、DDDs稳居第1位。胰岛素类各品种的金额和DDDs排序无明显浮动,排名基本稳定。其他降糖药中,α-葡萄糖苷酶抑制剂、胰岛素促泌剂、双胍类的销售金额、DDDs都位居前列。除格列喹酮、格列吡嗪外,其余降糖药各品种的DDC值均逐年小幅下降。大部分降糖类药物的B/A比值均接近1.00,说明患者同步性良好。结论天津医科大学代谢病医院降糖类药物中,胰岛素、α-葡萄糖苷酶抑制剂、胰岛素促泌剂占主导地位,降糖药的应用基本合理。

Objective To investigate the use of hypoglycemic agents in Tianjin Medical University Metabolic Diseases Hospital, so as to provide reference for clinical rational use of hypoglycemic agents. Methods A retrospective analysis method was used to analyze the varieties, sales amount, frequency of use(DDDs), daily average cost(DDC), and B/A of Tianjin Medical University Metabolic Diseases Hospital from 2015 to 2017. Results The sales volume and DDDs of hypoglycemic agents showed a trend of first decreasing and then increasing. Sales amount and DDDs of insulin were ranked the first. The sequence of sales amount and DDDs of various types of insulin had no obvious floating, and the rankings were basically stable. Sales amount and DDDs of α-glucosidase inhibitors, sulfonylureas, meglitinides, and metformin in the other antidiabetic drugs were ranked the top. Except gliquidone and glipizide, DDC of other hypoglycemic agents declined slightly year by year. The B/A ratio of hypoglycemic drugs were close to 1.00, indicating that patients had good synchronization. Conclusion Insulin,α-glucosidase inhibitors, sulfonylureas and meglitinides dominate the list of hypoglycemic drugs in Tianjin Medical University Metabolic Diseases Hospital, and the application of hypoglycemic agents is rational on the whole.